Discontinued drugs in 2006: renal, endocrine and metabolic drugs.
This perspective summarizes key compounds from the endocrine and metabolic area that were discontinued from clinical development during the calendar year 2006. This is a continuation in a series of perspectives of each of the editorial areas summarized by Expert Opinion on Investigational Drugs. The candidates covered in this summary were being developed for the treatment of diabetes and obesity, as well as for reproductive and urogenital health issues.
Colca
Jerry R
JR
Metabolic Solutions Development Company, 125 S. Kalamazoo Mall #202, Kalamazoo, MI 49007, USA. jerry.colca@kalmetres.com
D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D015507:Drugs, Investigational / Q000009:adverse effects / Q000627:therapeutic use; D007172:Erectile Dysfunction / Q000188:drug therapy; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy; D008297:Male; D009765:Obesity / Q000188:drug therapy; D047493:PPAR alpha / Q000819:agonists; D047495:PPAR gamma / Q000819:agonists; D011470:Prostatic Hyperplasia / Q000188:drug therapy; D013739:Testosterone / Q000819:agonists; D017211:Treatment Failure; D014549:Urinary Incontinence / Q000188:drug therapy
D015507:Drugs, Investigational; D047493:PPAR alpha; D047495:PPAR gamma; D013739:Testosterone